Nanjing Vazyme Medical Technology Co.,Ltd of Nanjing at MEDICA 2021 in Düsseldorf -- MEDICA - World Forum for Medicine
Manage stand orders
Select Option
Manufacturers Service

Nanjing Vazyme Medical Technology Co.,Ltd

Floor 1-3, Bldg C2, Red Maple Park Kechuang Rd, Qixia District, 210046 Nanjing
China
Telephone +86 400 9690586, +86 134 20988827
Fax +86 25 84365756
medical@vazyme.com

Submit your contact details

Provide your contact details to the exhibitor. Optionally, you may also add a personal message.

Please log in

You must be logged in to send the contact request.

An error has occurred

Please check your internet connection or try again later.

Message has been sent

Your message to the exhibitor was sent successfully.

This company is co-exhibitor of
Messe Düsseldorf China Ltd.

Hall map

MEDICA 2021 hall map (Hall 3): stand F94

Fairground map

MEDICA 2021 fairground map: Hall 3

Contact

Shenyu Wang

Leader
International Business

Phone
+86 134 2098 8827

Email
wangshenyu@vazyme.com

Please log in

You must be logged in to use matchmaking

Please log in for matchmaking

Registration is required to use the networking service and a separate registration for matchmaking. Please register for Matchmaking first.

Let's get started!

Welcome to Matchmaking. Would you like to get in touch with ?

Our products

Product category: Diagnostic rapid tests

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antigen Detection Kit(Colloidal Gold-Based)

Introduction: This kit is used for the qualitative detection of SARS-CoV-2 antigen presents in the human nasal swab, nasopharyngeal swab and saliva samples. For professional use only.

 

Advantages:

1.     SARS-CoV-2 Antigen Detection Kit is a lateral flow assay for the rapid, qualitative detection of the SARS-CoV-2 virus.

2.     Test results in 10 minutes with no instrumentation.

3.     Clinical performance: sensitivity 97.57% / specificity 99.29%.

4.     The SARS-CoV-2 Antigen Detection Kit for professional use is CE-Marked.

5. High-performance rapid test enables immediate treatment or isolation measures to minimize transmission.

 

Size: 1 test/kit, 5 tests/kit, 20 tests/kit

Sample type: Human nasal swab, nasopharyngeal swab and saliva samples in vitro.

   

More Less

Product category: Diagnostic rapid tests

Anti-SARS-CoV-2 Neutralizing Antibody ELISA Kit

Introduction: Using a blocking ELISA detection tool to qualitatively detect the neutralizing antibodies in serum/plasma, which provides a reference for evaluating the immune protection against the virus.

Advantages: Negative/Positive controls are contained for more accurate results.

Size:96 tests/kit

Sample type: Serum/Plasma  

More Less

Product category: Diagnostic rapid tests

SARS-CoV-2 RBD Protein IgG Detection Kit (Colloidal Gold-Based)

Introduction: This product is intended for the in vitro qualitative detection of RBD IgG antibody in human clinical samples,which provides a reference for evaluating the immune protection against the virus.

Advantages: Rapid detection of protective antibody (SARS CoV-2 RBD IgG) against COVID-19 in vitro.

Size:1 test/kit; 20 tests/kit

Sample type: Serum/Plasma/Whole blood  

More Less

Product category: Diagnostic rapid tests

2019-nCoV IgG/IgM Detection Kit (Colloidal Gold-Based)

Introduction: The kit can simultaneously monitor IgM and IgG, it could be a supplementary test for suspected cases with negative coronavirus nucleic acid detection to improve the diagnosis rate of suspected COVID-19 patients.

Advantages: Rapid detection of 2019-nCoV IgG/IgM in 10 minutes, achieve large-scale scan.

Size:20 tests/kit;50 tests/kit

Sample type: Serum/Plasma.

More Less

Product category: Diagnostic rapid tests

SARS-CoV-2 and Influenza A/B Virus Antigen Combined Detection Kit (Colloidal Gold-Based)

Introduction: The test kit is applicable to clinical qualitative detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen, influenza A virus antigen and influenza B virus antigen.

Advantages: Rapid detection of SARS-CoV-2 and Influenza A/B Virus Antigen in 10 minutes.

Size:20 tests/kit

Sample type: Nasal swab, Nasopharyngeal swab and Oropharyngeal swab samples  

More Less

Product category: Diagnostic rapid tests

Novel Coronavirus(SARS-CoV-2) and Influenza A/B Virus RT-QPCR

Products compositions: Detection Buffer  Enzyme Mix  Positive Control  Negative Control

Solution introduction: This kit is a real-time RT-PCR test intended for the qualitative detection of nucleic acids from the SARS-CoV-2, influenza A and influenza B virus in nasopharyngeal /oropharyngeal swab, sputum.

 

Key advantages:

Efficient: Simultaneous monitoring of SARS-CoV-2 and Influenza A/B Virus 

High Detection Sensitivity: 200 copies/mL of the detection limitation

Anti-contamination Systemd: UTP/UDG system can effectively degrade aerosol pollution to reduce the false-positive results. 

More Less

Product category: Diagnostic rapid tests

Nucleic Acid Detection Solution

Products compositions: Virus Sample Stabilizer; DNA/RNA Extraction Kit; Automatic nucleic acids extraction instrument; 2019-Novel Coronavirus (2019-nCoV) Triplex RT-qPCR Detection Kit; Real-Time Quantitative Thermal Cycler

 

Solution introduction: Collecting human samples by swabs, storing them in the stabilizer, extracting the samples to obtain nucleic acids, and then using real-time quantitative thermal cyclers to analyze human-derived nucleic acids based on fluorescent polymerase chain reaction (PCR) Etc. for quantitative/qualitative testing and melting curve analysis

 

Key advantages:

  Reliable operation: Cause the sample storage solution can inactivate the virus, and the swab is packaged individually to ensure safety and reliability

  Precise analysis: Clinical performance: PPA of 100%, NPA of 99.37%, OPA of 99.64%

  Efficient method: The automatic extraction link has strong magnetic force, and the recovery rate of magnetic beads is more than 95%

More Less

About us

Company portrait

Vazyme is a biotech enterprise dedicated to the R&D of technology and product featuring enzymes, antigens, antibodies and other functional proteins and polymer organic materials. Since founded in 2012 in Nanjing, China, Vazyme has established branches in more than 30 provinces and autonomous regions of China and distributes products to more than 30 countries and regions. Now Vazyme has more than 2000 employees in China, Southeast Asia and Europe and more than 40% of them are from the R&D department. Vazyme provides comprehensive solutions for life science and medical fields customers. Through Innovation in life science and engineering, Vazyme is committed to continuously improve human health.

Company data

Number of employees 1000-4999
Area of business Diagnostic tests